Dr. Wright is a developmental epidemiologist with transdisciplinary training in environmental health and stress mechanisms. She has a primary interest in early life (prenatal and early childhood) predictors of developmental diseases including asthma, obesity, neurobehavioral development, and lung growth and development. A particular focus is on the implementation of studies considering the role of both social (e.g., psychosocial stress, other socioeconomic risk factors) and physical (e.g., air pollution, chemicals, dietary factors, allergens) environmental factors in explaining health disparities among lower-SES urban populations. Dr. Wright is the PI and Director of the Asthma Coalition on Community, Environment, and Social Stress (ACCESS) project as well as the Programming of Intergenerational Stress Mechanisms (PRISM) study funded by the National Heart, Lung & Blood Institute (NHLBI). This research program explores underlying mechanisms by incorporating biomarkers of physiological pathways through which psychological stress as well as chemical stressors may influence health (e.g., altered hypothalamic-pituitary-adrenal axis functioning, altered maturation of the immune system, disruption of the autonomic nervous system, and epigenetics).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Wright did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Wright did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
